Bio-Rad Laboratories is a U.S.-based IVD and life science company with revenues of approximately $2.4 billion in 2025 across clinical diagnostics and life science research. Bio-Rad's clinical diagnostics segment specializes in quality controls, blood typing, diabetes monitoring (HbA1c), autoimmune testing, and infectious disease serology. The company is the global leader in laboratory quality controls — a high-margin, recurring revenue business supplying calibrators and controls to virtually every clinical laboratory globally. Bio-Rad accepted a binding offer to acquire Stilla Technologies in February 2025, expanding into digital PCR. The company's Droplet Digital PCR technology is gaining adoption in oncology research and liquid biopsy applications.
92 countries — 38 European, 18 Asia-Pacific, 22 Latin American, 11 Middle Eastern, and 3 North American countries.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• Strategic Directions — Quality Controls Leadership, Digital PCR Expansion, and Autoimmune Testing Through 2030
• Financial Performance — Revenue, Revenue by Segment, Revenue by Geography, EBITDA, and R&D 2023-2025
• SWOT Analysis — Competitive Advantages, Structural Vulnerabilities, Opportunities, and Risks
• Technological Know-How — Quality Controls, ddPCR, Blood Typing, and HbA1c Platforms
• Latest Products and Services — Stilla Integration, New Assays, and Innovation Pipeline
• M&A — Stilla Technologies Acquisition, Joint Ventures, and Partnerships 2023-2025
• Marketing Tactics — Quality Controls Market Strategy and Life Science Channel
• Organization and Management — Leadership, Structure, and Workforce
'
Table of Contents
1. Executive Summary
- Key findings and strategic implications
- Most significant developments 2024-2025
- Strategic recommendations
2. Strategic Directions
- Portfolio strategy and capital allocation priorities
- Technology investment focus areas
- Geographic expansion and market development
- Growth priorities through 2030
3. Financial Performance
- Revenue and revenue growth 2023-2025
- Revenue by segment 2023-2025
- Revenue by geography 2023-2025
- Operating income, margins, and EBITDA 2023-2025
- R&D investment 2023-2025
4. SWOT Analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
5. Technological Know-How
- Core technology capabilities and IP portfolio
- AI and digital diagnostics investments
- Key platform systems and technology milestones
6. Latest Products and Services
- Recent product and platform launches 2023-2025
- Key analyzer and reagent portfolio
- Innovation pipeline and development programs
7. M&A
- Acquisitions, divestitures, and partnerships 2023-2025
8. Marketing Tactics
- Segment and channel positioning
- Reagent rental and placement strategy
- Key account and GPO strategy
9. Organization and Management
- Leadership and executive team
- Organizational structure and key changes
- Workforce size and developments
10. Appendix
- Research methodology
- Abbreviations and definitions
- List of tables and figures
List of Tables
Table 1. Bio-Rad Laboratories — Key Financial Metrics Summary 2023-2025
Table 2. Bio-Rad Laboratories — Revenue by Segment 2023-2025
Table 3. Bio-Rad Laboratories — Revenue by Geography 2023-2025
Table 4. Bio-Rad Laboratories — R&D Investment 2023-2025
Table 5. Bio-Rad Laboratories — SWOT Analysis
Table 6. Bio-Rad Laboratories — Core Technology Capabilities and Key Platforms
Table 7. Bio-Rad Laboratories — Key Analyzers and Reagent Portfolio
Table 8. Bio-Rad Laboratories — M&A Activity Summary 2023-2025
Table 9. Bio-Rad Laboratories — Key Management and Leadership
Table 10. Bio-Rad Laboratories — Strategic Priorities 2025-2030
